The Retention Crisis in Femtech: Why Employer Renewals Will Expose Your Engagement Gap
How contract structure, low utilization, and outcomes‑based purchasing are bringing femtech's engagement problem to the surface.
The femtech industry has a story it has been telling itself for the last three years.
The story goes like this: the D2C model was always fragile — dependent on paid acquisition, vulnerable to churn, and held together by cheap capital that made replacing lost users cheaper than retaining them. When funding contracted, that model broke. But femtech was already pivoting. Employer and payer contracts were the answer. B2B2C was the durable revenue model, the path to scale, the proof that women’s health technology had grown up.
The story is not wrong. The pivot is real. One of the sector’s most scaled B2B2C platforms now covers more than 17 million lives globally through employer benefit plans. The market is actively moving from volatile D2C models toward stable B2B corporate integration. These are real shifts.
What the story leaves out is this: the pivot imported the engagement problem. It didn’t solve it. It just changed the audience that would eventually notice.
That audience — employers, payers, and HR benefits leaders — is noticing now. And the mechanism forcing the issue is something femtech platforms have underestimated: the contract renewal cycle.
The Story Femtech Tells Itself About D2C and B2B2C
Before we get to the renewal crisis, it’s worth naming why the B2B2C pivot felt like a solution.
D2C femtech was visibly broken by 2022. Acquisition costs were high, churn was endemic, and retention metrics that had been obscured by a constant flow of replacement users became impossible to ignore once that flow slowed. The employer and payer channel looked like an escape hatch: larger contracts, stickier revenue, institutional credibility, and a buyer — the HR or Benefits leader — who wasn’t going to churn the way a consumer would.
What the pivot didn’t change was the underlying architecture. The platforms that moved into B2B2C brought their engagement models with them. Those models were built for acquisition, not for the sustained behavioral change that produces clinical outcomes. That distinction didn’t matter much in the early years of employer contracts. It matters now.
The PMPM Contract Structure That Hid Femtech’s Utilization Problem
To understand why employer renewals are the inflection point, you have to understand how most femtech platforms sold into the enterprise in the first place.
The dominant contract structure has been per member per month (PMPM) pricing. Under PMPM, an employer pays a fixed monthly fee based on their covered population — not their engaged one. A company covering 5,000 employees pays the same fee whether 500 of those employees actively use the platform or 50 do.
This matters because the utilization data for digital health point solutions has always been damaging, and PMPM pricing made it easy to avoid surfacing it. Industry benchmarks tell a clear story: most digital health solutions struggle to achieve even a 5 to 10 percent enrollment rate among eligible employees. Leading programs reach 20 to 30 percent. That means the average femtech platform, operating at baseline industry performance, is delivering meaningful engagement to fewer than one in ten of the employees an employer is paying to cover.
Under PMPM, this stays invisible. The invoice doesn’t change. The renewal conversation doesn’t require the vendor to explain the gap between covered lives and active users. The problem exists — it’s just not in the contract.
One benefits industry analyst put it plainly: per member per month contracts were a gift to digital health companies, particularly those struggling with utilization.
That gift is expiring.
Shorter Contracts, Tougher Renewals: The New Employer Expectations
Most employers are now reviewing their digital health vendor portfolios annually. The Peterson Health Technology Institute’s 2025 State of Digital Health Purchasing survey found that 73 percent of purchasers use short-term contracts of two years or less. The contract cycles that gave femtech platforms room to grow into their utilization claims are compressing.
More critically, what employers are asking at renewal has fundamentally shifted.
A major national health plan’s 2026 employer trends report is explicit: vendors are facing greater pressure to demonstrate measurable outcomes — not just rely on access or utilization metrics. The Business Group on Health, which represents major U.S. employers, issued direct purchasing guidance for 2025: Finance and Benefit teams should insist on outcomes-based contracts that require vendors to demonstrate improvement in health outcomes and deliver promised returns.
This is not future-state language. This is the guidance sitting in front of HR and Benefits leaders at large employers right now, as they approach renewal conversations with their femtech vendors.
The WTW survey data puts a number on the shift: nearly 80 percent of employers say they need to see a clear return on investment from their point solution partners. A venture capital principal advising digital health investments described what this looks like in practice: “I’m seeing a much higher bar for a two-year ROI. If point solutions don’t deliver, or if employees aren’t utilizing services, employers and EAPs are quickly moving on.”
ROI Benchmarks, Self‑Reported Outcomes, and the Validation Gap
One of the sector’s most cited B2B2C case studies offers the clearest benchmark for what a passing grade now looks like. It reports a 4.2x clinical and business return on investment, meaning payers saw more than four dollars of value for every dollar they spent, plus per‑member savings of about $4,600 — calculated as total savings divided by the number of participating members — through a major payer partnership. These numbers are real and they matter. They also reveal how high the bar has been set — and how few femtech platforms have the measurement infrastructure to produce equivalent claims.
It’s worth noting that the productivity and return-to-work figures in that case are self-reported by members. Sophisticated benefits buyers are already flagging this. Third-party validated outcomes — independently verified rather than vendor-curated — are becoming the next threshold. The Validation Institute, which independently verifies performance claims for healthcare solutions, reported significant growth in companies seeking validation in 2024, describing it as “a key differentiator for any company looking to win more business and be seen as a credible solution in the eyes of benefits buyers.” No femtech platforms appeared on their 2024 validated list.
Point‑Solution Fatigue, M&A, and Femtech’s Place in the Benefits Stack
Femtech doesn’t face the renewal reckoning in isolation. It competes inside a broader employer benefits landscape that is actively consolidating — and femtech’s typical positioning as a point solution makes it directly exposed to what analysts are now calling point solution fatigue.
The average large employer manages ten or more point solution vendor relationships. Multiple portals, multiple logins, fragmented data, no unified view of what’s working. Benefit leaders cannot tell executives what the return is across their vendor portfolio. The administrative burden alone is driving consolidation — over half of employers are expected to shift toward integrated engagement platforms by 2027.
The digital health M&A data reflects this: transaction volume increased 37 percent in 2025 compared to 2024, driven by platforms absorbing point solutions that couldn’t survive independent scrutiny.
The femtech companies most at risk in this wave are those that cannot demonstrate three things: measurable clinical outcomes, clean data that survives external review, and integration into a broader care architecture rather than functioning as a standalone app with a monthly invoice.
The Structural Problem Beneath the Commercial One
Every layer of this crisis points to the same root cause: engagement was assumed, not engineered.
The D2C model rewarded acquisition. The PMPM model rewarded contract signatures. Neither required femtech platforms to answer the harder question — in the case of a menopause‑focused benefits platform, what actually keeps a midlife woman showing up, progressing, and improving in ways her employer can measure and verify?
Enrollment is not engagement. Engagement is not outcomes. And in the current purchasing environment, outcomes are not outcomes unless they can survive independent scrutiny.
The platforms that will produce validated ROI in 2026 and 2027 are the ones that treated engagement as a clinical architecture problem, not a marketing one. They built predictive models for disengagement. They created intervention logic that fires before a user goes quiet. They connected behavioral signals to outcomes data in ways that hold up under third-party review.
Most femtech platforms didn’t build this. Not because their teams weren’t capable, but because the funding environment and contract structures didn’t require it. The requirement is arriving now, through the renewal conversation.
Where Metis Comes In
I spent 15 years inside enterprise Customer Success before moving into femtech and women’s health coaching. I’ve sat inside the platform — I understand where engagement architecture breaks down, why it gets deprioritized in the sprint toward contract signatures, and what it actually takes to build a retention system that generates defensible outcomes data.
I also understand, from the practitioner side, what meaningful engagement looks like for the specific populations femtech platforms serve — whether the focus is fertility, pregnancy, metabolic health, or menopause. In midlife care for example, women navigating hormonal transition are not passive consumers. They know when they’re being managed versus genuinely supported. Generic engagement sequences and low‑touch onboarding don’t just produce poor outcomes — they produce outcomes that are visibly poor to the user before they’re visible in the data.
That combination — fluency in the product, data, and operational constraints that shape engagement inside the platform, and fluency in what a sophisticated employer buyer will require at renewal — is the work Metis does on engagement architecture.
My gravitational pull is on the femtech company side. I spent 15 years in enterprise Customer Success and the last six years inside femtech companies as a health coach practitioner, which is how I’ve seen both the engagement problems and what it takes to measure real improvement. The mission behind Metis is to use that experience to help femtech teams design engagement that can be measured and defended in front of employer buyers, experienced as meaningful support by the women they serve, and reflected in stronger recurring revenue and retention. This is the work that has to happen before the renewal conversation — not during it, and not after a contract has already been lost. Now.
Metis is designed to work with a small number of women’s health technology platforms per year on a retained basis, with engagements structured around predictive engagement strategy, retention architecture, and outcomes measurement frameworks that hold up under both consumer and enterprise scrutiny.
If your platform is approaching a renewal cycle, the window to build what you need is open. It won’t stay that way.
Inquiries about Metis advisory work:
carla@metisfemtech.com | metisfemtech.com
Selected data points in this article draw on publicly available research on digital health utilization, employer benefits purchasing, outcomes‑based contracts, and digital health M&A, including work by Peterson Health Technology Institute, Business Group on Health, WTW, the Validation Institute, and leading women’s health vendors. A more detailed source list will be published in the Sources & Methodology section of the Metis Femtech Q2 2026 Intelligence Brief, “The Retention Reckoning,” scheduled for release in late June 2026.
Carla Moss is the founder of Metis Femtech Consultancy, a strategic advisory designed to help women’s health technology companies build AI-native customer success systems that sustain engagement, outcomes, and retention. She brings 15 years of enterprise Customer Success experience and 6+ years as a health coach practitioner inside digital health, combined with her work as a National Board-Certified Health and Wellness Coach specializing in midlife women’s health.
The Metis Engagement Architecture Design Process
A strategic advisory engagement designed to help women’s health technology companies build AI-native customer success systems that sustain engagement, outcomes, and retention.